Overview

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Status:
Recruiting

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

A prospective, randomized, comparative study to evaluate efficacy of anticancer chemotherapy in predicting prognosis and determining chemotherapy method in early Hormone Receptor-positive breast cancer patients with clinicopathological high risk and GenesWell™ BCT low risk at multi-center in Korea

Phase:

N/A

Details

Lead Sponsor:

Gencurix, Inc.

Treatments:

Antineoplastic Agents
Hormones